Newsmeme!
Discover News you didn't know existed
Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) (Frankfurt, Prime Standard: QIA) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).
Astrocytoma is a malignant, or cancerous, type of brain tumor. This type of tumor arises from small, star-shaped cells in the brain called astrocytes. Astrocytes are one of several types of supporting cells in the brain called glial cells.
Qiagen N.V. / QIAGEN Reports Strong Fourth Quarter and Fiscal 2009 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
VENLO, Netherlands -- QIAGEN N.V. today announced the results of operations for the fourth quarter and the fiscal year ended December 31, 2009.
Pfizer Inc. and DxS, a wholly owned subsidiary of Qiagen N.V. have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed.
Northwest Biotherapeutics, Inc. , a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Â Led from its Los Angeles headquarters, Market Media Connect will support Northwestâs communication objectives as the company moves into the next phase of its ...
A YOUNG mum is called on the public to help her beat a deadly brain tumour.
A Pennsylvania judge denied a motion by Rohm and Haas to forbid mention of other McCullom Lake brain cancers in its upcoming trial on behalf of one of the first plaintiffs.
Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been ...
Pfizer Inc. and DxS (a wholly owned subsidiary of Qiagen N.V.) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |